A number of studies have identified MCT4 lactate transport as a potential resistance mechanism to MCT1 inhibition [16, 38, 39] suggesting that where MCT4 is present, the tumor may be refractory to AZD3965. This evidence concerns the gene SLC16A3 and neoplasm.